BC Extra | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of...
BC Extra | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said co-founder C. Frank Bennett will become CSO, with Eric Swayze succeeding him as SVP of research. Bennett will remain the antisense oligonucleotide company’s franchise leader for neurology drug discovery. Swayze...
BC Extra | Nov 16, 2019
Company News

Novartis gains CHMP support in MS, Cushing syndrome

Included November roundup of EMA’s CHMP were a positive opinion for Mayzent siponimod, which Novartis hopes will become the treatment of choice for active secondary progressive multiple sclerosis. CHMP backed an MAA for Mayzent to...
BC Extra | Oct 24, 2019
Company News

Management tracks: bluebird's Walsh departing as chief strategy officer; plus JDRF, Akcea, Rigel, Elicio and Progenity

bluebird bio Inc. (NASDAQ:BLUE) Chief Strategy Officer Jeffrey Walsh will step down, effective Jan. 6, 2020. The gene therapy company said CFO Chip Baird and CBO Joanne Smith-Farrell will assume additional corporate development and strategic...
BC Innovations | Aug 29, 2019
Distillery Techniques

Single cell metabolic analysis to predict therapeutic response and identify targets for NSCLC

TECHNIQUES CATEGORY: Assays and screens TECHNOLOGY: Diagnostic assays High-throughput metabolic analysis of single tumor cells from liquid biopsy samples could be used to predict response to therapy and identify targets associated with drug resistance in...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Week In Review | Nov 2, 2018
Company News

Rigel grants Kissei Asian rights to Tavalisse

Rigel granted Kissei exclusive rights to develop and commercialize Tavalisse fostamatinib for all current and future indications in Japan, China, Taiwan and Korea. Rigel said it has the option to co-develop the product in the...
BC Week In Review | Sep 28, 2018
Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best...
BC Extra | Sep 25, 2018
Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best overall...
Items per page:
1 - 10 of 467
BC Extra | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of...
BC Extra | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said co-founder C. Frank Bennett will become CSO, with Eric Swayze succeeding him as SVP of research. Bennett will remain the antisense oligonucleotide company’s franchise leader for neurology drug discovery. Swayze...
BC Extra | Nov 16, 2019
Company News

Novartis gains CHMP support in MS, Cushing syndrome

Included November roundup of EMA’s CHMP were a positive opinion for Mayzent siponimod, which Novartis hopes will become the treatment of choice for active secondary progressive multiple sclerosis. CHMP backed an MAA for Mayzent to...
BC Extra | Oct 24, 2019
Company News

Management tracks: bluebird's Walsh departing as chief strategy officer; plus JDRF, Akcea, Rigel, Elicio and Progenity

bluebird bio Inc. (NASDAQ:BLUE) Chief Strategy Officer Jeffrey Walsh will step down, effective Jan. 6, 2020. The gene therapy company said CFO Chip Baird and CBO Joanne Smith-Farrell will assume additional corporate development and strategic...
BC Innovations | Aug 29, 2019
Distillery Techniques

Single cell metabolic analysis to predict therapeutic response and identify targets for NSCLC

TECHNIQUES CATEGORY: Assays and screens TECHNOLOGY: Diagnostic assays High-throughput metabolic analysis of single tumor cells from liquid biopsy samples could be used to predict response to therapy and identify targets associated with drug resistance in...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Week In Review | Nov 2, 2018
Company News

Rigel grants Kissei Asian rights to Tavalisse

Rigel granted Kissei exclusive rights to develop and commercialize Tavalisse fostamatinib for all current and future indications in Japan, China, Taiwan and Korea. Rigel said it has the option to co-develop the product in the...
BC Week In Review | Sep 28, 2018
Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best...
BC Extra | Sep 25, 2018
Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best overall...
Items per page:
1 - 10 of 467